ZA200404291B - Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor. - Google Patents

Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor. Download PDF

Info

Publication number
ZA200404291B
ZA200404291B ZA200404291A ZA200404291A ZA200404291B ZA 200404291 B ZA200404291 B ZA 200404291B ZA 200404291 A ZA200404291 A ZA 200404291A ZA 200404291 A ZA200404291 A ZA 200404291A ZA 200404291 B ZA200404291 B ZA 200404291B
Authority
ZA
South Africa
Prior art keywords
csf
biologically active
imac
process according
purification
Prior art date
Application number
ZA200404291A
Other languages
English (en)
Inventor
Gaberc Porekar Vladka
Viktor Menart
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of ZA200404291B publication Critical patent/ZA200404291B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
ZA200404291A 2001-12-19 2004-06-01 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor. ZA200404291B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200100322A SI21102A (sl) 2001-12-19 2001-12-19 Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika

Publications (1)

Publication Number Publication Date
ZA200404291B true ZA200404291B (en) 2005-08-05

Family

ID=20433022

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200404291A ZA200404291B (en) 2001-12-19 2004-06-01 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor.

Country Status (22)

Country Link
US (1) US20050159589A1 (xx)
EP (2) EP1458757B1 (xx)
JP (1) JP4454311B2 (xx)
KR (1) KR20040071212A (xx)
CN (1) CN1606568A (xx)
AT (1) ATE423136T1 (xx)
AU (1) AU2002366275B2 (xx)
BR (1) BR0215191A (xx)
CA (1) CA2469984C (xx)
DE (1) DE60231243D1 (xx)
HK (1) HK1064681A1 (xx)
HR (1) HRP20040572A2 (xx)
HU (1) HUP0402547A3 (xx)
IL (2) IL162448A0 (xx)
MX (1) MXPA04006076A (xx)
NO (1) NO20042967L (xx)
NZ (1) NZ533305A (xx)
PL (1) PL207775B1 (xx)
RU (1) RU2358980C2 (xx)
SI (2) SI21102A (xx)
WO (1) WO2003051922A1 (xx)
ZA (1) ZA200404291B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
DK1439191T3 (da) * 2004-01-19 2006-08-14 Ares Trading Sa Proces til oprensning af bakterielt udtrykte proteiner
EP1803464A4 (en) * 2004-09-17 2009-09-09 Cellgentech Inc TOPICAL PREPARATION FOR THE TREATMENT OF SKIN DISEASES
US20090136444A1 (en) * 2005-02-15 2009-05-28 Apollo Life Sciences Limited molecule and chimeric molecules thereof
WO2006097944A2 (en) * 2005-03-17 2006-09-21 Zenotech Laboratories Limited Process for the purification of recombinant granulocyte-colony stimulating factor
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP1878739A1 (en) * 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
ES2476915T3 (es) 2007-08-27 2014-07-15 Ratiopharm Gmbh Formulación líquida de conjugado de G-CSF
JP2009073819A (ja) * 2007-08-29 2009-04-09 Fujifilm Corp 生理活性物質の精製方法
US20120093765A1 (en) * 2009-06-16 2012-04-19 Lupin Limited Process for purification of recombinant human granulocyte colony stimulating factor
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
EP3040346B1 (en) * 2010-03-30 2018-02-28 Octapharma AG Process for the purification of granulocyte colony stimulating factor, g-csf
CA2831787A1 (en) 2011-03-29 2012-10-04 Glaxosmithkline Llc Buffer system for protein purification
CN103215340A (zh) * 2012-01-19 2013-07-24 江苏粒福特生物科技有限公司 一种新颖的粒细胞制备及其抗癌活性检测方法
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
EP0215126B1 (en) 1985-02-08 1991-07-31 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US5055555A (en) 1989-01-05 1991-10-08 Helmut Sassenfeld Purification of G-CSF
US5169936A (en) 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5932102A (en) 1998-01-12 1999-08-03 Schering Corporation Immobilized metal, affinity chromatography
FR2796071B1 (fr) * 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes

Also Published As

Publication number Publication date
HUP0402547A2 (hu) 2005-03-29
EP2053061A1 (en) 2009-04-29
SI21102A (sl) 2003-06-30
CN1606568A (zh) 2005-04-13
HUP0402547A3 (en) 2010-01-28
RU2004121982A (ru) 2005-04-20
HRP20040572A2 (en) 2005-06-30
NO20042967L (no) 2004-09-07
BR0215191A (pt) 2004-11-16
JP4454311B2 (ja) 2010-04-21
US20050159589A1 (en) 2005-07-21
CA2469984C (en) 2014-05-20
EP1458757A1 (en) 2004-09-22
CA2469984A1 (en) 2003-06-26
AU2002366275A1 (en) 2003-06-30
KR20040071212A (ko) 2004-08-11
MXPA04006076A (es) 2005-02-24
IL162448A0 (en) 2005-11-20
EP1458757B1 (en) 2009-02-18
PL207775B1 (pl) 2011-01-31
SI1458757T1 (sl) 2009-10-31
AU2002366275B2 (en) 2009-04-02
RU2358980C2 (ru) 2009-06-20
WO2003051922A1 (en) 2003-06-26
NZ533305A (en) 2005-11-25
PL369669A1 (en) 2005-05-02
JP2005525304A (ja) 2005-08-25
ATE423136T1 (de) 2009-03-15
DE60231243D1 (de) 2009-04-02
IL162448A (en) 2010-12-30
HK1064681A1 (en) 2005-02-04

Similar Documents

Publication Publication Date Title
AU2002366275B2 (en) Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
Yoshimura et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines.
EP0401384B1 (en) Chemically modified granulocyte colony stimulating factor
EP1037657B1 (en) Alpha-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
EP0228452B1 (en) Protein purification
KR910700336A (ko) 조작형 플라스미노겐 활성화제의 유도체
EP1878739A1 (en) One step IMAC (MCAC) purification of proteins
US5196323A (en) Process for preparing and purifying alpha-interferon
EA035448B1 (ru) СПОСОБ ОЧИСТКИ рчГ-КСФ
JP2566919B2 (ja) α−インタ−フエロンの製造方法
RU2278870C2 (ru) Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе
US20080293924A1 (en) Process For the Isolation and/or Purification of Proteins
JP3200850B2 (ja) ヒトbcdfの精製法
KR100531670B1 (ko) 인체 인터페론 알파의 제조방법
JPH022390A (ja) 新規なヒト顆粒球マクロファージコロニー刺激因子
JPH11335395A (ja) 精製ヒトアクチビン及びその製造方法
EP0446850A2 (en) Process for purifying recombinant human beta-interferon
Rosenberg 4894440 Method of isolating megakaryocyte stimulatory factor
JPH07103041B2 (ja) 悪性腫瘍治療補助剤